Escitalopram in the treatment of major depressive disorder: a meta-analysis.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Current Medical Research and Opinion

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1185/03007990802622726 PMID 19210149
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Escitalopram and duloxetine in the treatment of major depressive disorder: a pooled analysis of two trials

  2008cited by this paper
• A meta-analysis of clinical trials comparing reboxetine, a norepinephrine reuptake inhibitor, with selective serotonin reuptake inhibitors for the treatment of major depressive disorder.

  2008cited by this paper
• Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs.

  2008cited by this paper
• Differential regulation of serotonin-1A receptor-stimulated [35S]GTP gamma S binding in the dorsal raphe nucleus by citalopram and escitalopram.

  2008cited by this paper
• Escitalopram in major depressive disorder: a multicenter, randomized, double‐blind, fixed‐dose, parallel trial in a Chinese population

  2008cited by this paper
• Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.

  2007cited by this paper
• Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study*

  2007cited by this paper
• Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents.

  2007cited by this paper
• A comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorder

  2007cited by this paper
• Which antidepressants have demonstrated superior efficacy? A review of the evidence

  2007cited by this paper
• Double-Blind Comparison of Escitalopram and Duloxetine in the Acute Treatment of Major Depressive Disorder

  2007cited by this paper
• Efficacy of Duloxetine and Selective Serotonin Reuptake Inhibitors: Comparisons as Assessed by Remission Rates in Patients With Major Depressive Disorder

  2007cited by this paper
• Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trial*

  2007cited by this paper
• The Influence of Baseline Severity on Efficacy of Escitalopram and Citalopram in the Treatment of Major Depressive Disorder: An Extended Analysis

  2006cited by this paper
• Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis.

  2006cited by this paper
• Escitalopram versus venlafaxine XR in the treatment of depression

  2006cited by this paper
• Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies.

  2006cited by this paper
• A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients

  2006cited by this paper
• The Montgomery Asberg and the Hamilton ratings of depression: a comparison of measures.

  2006cited by this paper
• A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder

  2006cited by this paper
• The pharmacology of citalopram enantiomers: the antagonism by R-citalopram on the effect of S-citalopram.

  2006cited by this paper
• Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.

  2006cited by this paper
• Effective dose of escitalopram in moderate versus severe DSM-IV major depression.

  2006cited by this paper
• Medication augmentation after the failure of SSRIs for depression.

  2006cited by this paper
• Comparison of escitalopram and citalopram in outpatients with severe major depressive disorder: a prospective, naturalistic, 8-week study

  2006cited by this paper
• A randomized, double-blind, 24‐week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder*

  2005cited by this paper
• Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder

  2005cited by this paper
• Escitalopram in the treatment of depressed elderly patients.

  2005cited by this paper
• A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder.

  2004cited by this paper
• Executive Dysfunction, Heart Disease Burden, and Remission of Geriatric Depression

  2004cited by this paper
• Escitalopram continuation treatment prevents relapse of depressive episodes.

  2004cited by this paper
• A Randomised Study Comparing Escitalopram with Venlafaxine XR in Primary Care Patients with Major Depressive Disorder

  2004cited by this paper
• Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder

  2004cited by this paper
• Escitalopram (10–20 mg/day) is effective and well tolerated in a placebo‐controlled study in depression in primary care

  2003cited by this paper
• The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors.

  2003cited by this paper
• Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis.

  2002cited by this paper
• Efficacy Comparison of Escitalopram and Citalopram in the Treatment of Major Depressive Disorder: Pooled Analysis of Placebo-Controlled Trials

  2002cited by this paper
• Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients.

  2002cited by this paper
• Meta-analytical studies on new antidepressants.

  2001cited by this paper
• Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors

  2001cited by this paper
• Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability.

  2000cited by this paper
• Detecting and describing heterogeneity in meta-analysis.

  1998cited by this paper
• SSRIs versus tricyclic antidepressants in depressed inpatients: A meta‐analysis of efficacy and tolerability

  1998cited by this paper
• Small sample inference for fixed effects from restricted maximum likelihood.

  1997cited by this paper
• Early desensitization of somato-dendritic 5-HT1A autoreceptors in rats treated with fluoxetine or paroxetine

  1995cited by this paper
• A New Depression Scale Designed to be Sensitive to Change

  1979cited by this paper
• A RATING SCALE FOR DEPRESSION

  1960cited by this paper

• Multi-Layered Antidepressant Mechanisms of Gami-Soyosan in a Corticosterone-Induced Mouse Model

  2026cites this paper
• Two-stage Bayesian network meta-analysis of individualized treatment rules for multiple treatments with siloed data

  2025cites this paper
• Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-Release Tablets in Depression With Anhedonia: A Single-Arm, Multicenter Clinical Study

  2025cites this paper
• Efficacy and Safety of Ammoxetine in Major Depressive Disorder

  2025cites this paper
• A Placebo-Controlled Randomized Trial of the Effects of Escitalopram on Depressive Symptoms and Immune Function in People With HIV

  2025cites this paper
• Comparative analysis of antidepressant-like effects of five herbal essential oils on mice with reserpine-induced depression

  2024cites this paper
• Unraveling the potential of Morinda officinalis oligosaccharides as an adjuvant of escitalopram in depression treatment and exploring the underlying mechanisms.

  2024cites this paper
• The protective role of ginsenoside Rg3 in heart diseases and mental disorders

  2024cites this paper
• Comparative effectiveness of selective serotonin reuptake inhibitors (SSRIs) for depression in 43,061 older adults with chronic somatic diseases: A Danish target trial emulation study.

  2024cites this paper
• Pharmacometabolomics in Drug Disposition, Toxicity, and Precision Medicine

  2024influential citation
• Unraveling the potential of vitamins C and D as adjuvants in depression treatment with escitalopram in an LPS animal model

  2024cites this paper
• Personality change in a trial of psilocybin therapy v. escitalopram treatment for depression

  2023cites this paper
• Поєднання тривоги та депресії: чому іноді лікування не допомагає?

  2023cites this paper
• Antidepressants or running therapy: Comparing effects on mental and physical health in patients with depression and anxiety disorders.

  2023cites this paper
• A phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial to verify the efficacy and safety of ansofaxine (LY03005) for major depressive disorder

  2023cites this paper
• Impact of Sertraline, Fluoxetine, and Escitalopram on Psychological Distress among United States Adult Outpatients with a Major Depressive Disorder

  2023cites this paper
• [Effectiveness, safety and adherence to therapy with Elicea Q-Tab in real clinical practice].

  2023cites this paper
• Neuroprotective effect of geraniol on neurological disorders: a review article

  2022cites this paper
• Males and females differ in reported sexual functioning with escitalopram treatment for major depressive disorder: A CAN-BIND-1 study report

  2022cites this paper
• Ginsenosides in central nervous system diseases: Pharmacological actions, mechanisms, and therapeutics

  2022cites this paper
• Selective Serotonin Reuptake Inhibitors within Cells: Temporal Resolution in Cytoplasm, Endoplasmic Reticulum, and Membrane

  2022cites this paper
• A Review of Clinical Studies Assessing the Therapeutic Efficacy of Escitalopram: A Step Towards Development.

  2022cites this paper
• Pretreatment anxious depression as a predictor of side effect frequency and severity in escitalopram and aripiprazole adjunctive therapy

  2022influential citation
• Pain severity and pain interference during major depressive episodes treated with escitalopram and aripiprazole adjunctive therapy: a CAN-BIND-1 report.

  2022cites this paper
• Baseline Anxiety, and Early Anxiety/Depression Improvement in Anxious Depression Predicts Treatment Outcomes with Escitalopram: A CAN-BIND-1 Study Report.

  2021cites this paper
• Effects of escitalopram therapy on resting-state functional connectivity of subsystems of the default mode network in unmedicated patients with major depressive disorder

  2021cites this paper
• Efficacy, Safety, and Tolerability of Ansofaxine (LY03005) Extended-Release Tablet for Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding, Phase 2 Clinical Trial

  2021influential citation
• Neuroprotective Potential of Limonene and Limonene Containing Natural Products

  2021cites this paper
• Incorporating clinical research into recommendations for addressing global mental health needs: Updating the World Health Organization's Essential Medicines List.

  2021cites this paper
• The methodological quality of individual participant data meta-analysis on intervention effects: systematic review

  2021cites this paper
• Si-Ni-San Prevents Reserpine-Induced Depression by Inhibiting Inflammation and Regulating CYP450 Enzymatic Activity

  2020cites this paper
• A COMPARATIVE STUDY EVALUATING THE DEPRESSIVE SYMPTOMS AND FUNCTIONAL OUTCOME IN PATIENTS TREATED WITH SELECTIVE SEROTONIN REUPTAKE INHIBITORS V/S SEROTONIN–NOREPINEPHRINE REUPTAKE INHIBITORS AS ANTIDEPRESSANT AGENTS IN MAJOR DEPRESSIVE DISORDER

  2020cites this paper
• Corticotropin-releasing hormone 1 receptor antagonism attenuates chronic unpredictable mild stress-induced depressive-like behaviors in rats.

  2020cites this paper
• Comparative Efficacy and Safety of Escitalopram versus Desvenlafaxine in Postmenopausal Women with Depression and Anxiety: A Randomized, Open-Label, Comparative Trial

  2019cites this paper
• Antidepressant active ingredients from herbs and nutraceuticals used in TCM: pharmacological mechanisms and prospects for drug discovery.

  2019cites this paper
• Which first-line antidepressant?

  2019cites this paper
• Antidepressant-like Effect of Citrus sinensis (L.) Osbeck Essential Oil and Its Main Component Limonene on Mice.

  2019cites this paper
• Ginsenoside Rg1 attenuates chronic unpredictable mild stress-induced depressive-like effect via regulating NF-κB/NLRP3 pathway in rats.

  2019cites this paper
• Analytical methodologies for the enantiodetermination of citalopram and its metabolites.

  2019cites this paper
• Spatio-temporal dynamics of EEG features during sleep in major depressive disorder after treatment with escitalopram: a pilot study

  2019cites this paper
• Characteristics of patients with depression initiating or switching antidepressant treatment: baseline analyses of the PERFORM cohort study

  2018cites this paper
• The comparative effectiveness of electroencephalographic indices in predicting response to escitalopram therapy in depression: A pilot study.

  2018cites this paper
• A Prospective 8-Week Comparison of Cost-Effectiveness of two Antidepressants: Escitalopram and Milnacipran at Tertiary Heath Care Center

  2018cites this paper
• Factors associated with failure to achieve remission and with relapse after remission in patients with major depressive disorder in the PERFORM study

  2017cites this paper
• Efficacy of escitalopram monotherapy in the treatment of major depressive disorder

  2017influential citation
• Efficacy of escitalopram in the treatment of social anxiety disorder: A meta-analysis versus placebo.

  2016cites this paper
• Evidence-Based Selection and Use of Antidepressants in Psychiatric Practice

  2016cites this paper
• Residual symptoms and functionality in depressed outpatients: A one-year observational study in Switzerland with escitalopram.

  2016cites this paper
• Integrin β3 Haploinsufficiency Modulates Serotonin Transport and Antidepressant-Sensitive Behavior in Mice

  2015cites this paper
• Open prospective study of ziprasidone in patients with schizophrenia with depressive symptoms: A multicenter study

  2015cites this paper
• The international Study to Predict Optimized Treatment in Depression (iSPOT-D): outcomes from the acute phase of antidepressant treatment.

  2015cites this paper
• Does escitalopram reduce neurotoxicity in major depression?

  2015cites this paper
• Vortioxetine: a meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder.

  2015cites this paper
• Pharmacotherapeutic strategies for patients treated for depression in UK primary care: a database analysis

  2015cites this paper
• Treatment of Adults With Treatment-Resistant Depression: Electroconvulsive Therapy Plus Antidepressant or Electroconvulsive Therapy Alone? Evidence From an Indirect Comparison Meta-Analysis

  2015cites this paper
• Geraniol produces antidepressant-like effects in a chronic unpredictable mild stress mice model.

  2015cites this paper
• A decade of individual participant data meta-analyses: A review of current practice.

  2015cites this paper
• What to expect from a third step in treatment resistant depression: A prospective open study on escitalopram

  2015influential citation
• [Evidence-based choice and antidepressants treatment in psychiatry].

  2015cites this paper
• Prophylactic efficacy of fluoxetine, escitalopram, sertraline, paroxetine, and concomitant psychotherapy in major depressive disorder: outcome after long-term follow-up.

  2015cites this paper
• Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders

  2015cites this paper
• Anhedonia in Major Depressive Disorder: Exploration of a Predictive Clinical Phenotype

  2015influential citation
• Could neuroplasticity be an answer to different antidepressants efficacy among individuals

  2014cites this paper
• Effect of symptom severity on efficacy and safety of aripiprazole adjunctive to antidepressant monotherapy in major depressive disorder: a pooled analysis.

  2014cites this paper
• A Review of Vilazodone, Serotonin, and Major Depressive Disorder

  2014cites this paper
• A comparative review of escitalopram, paroxetine, and sertraline: are they all alike?

  2014influential citation
• Serotonergic receptor mechanisms underlying antidepressant-like action in the progesterone withdrawal model of hormonally induced depression in rats.

  2013cites this paper
• Impact of Antidepressants on Cytokine Production of Depressed Patients in Vitro

  2013cites this paper
• A randomized, placebo-controlled, double-blind trial of sertraline for postpartum depression

  2013cites this paper
• Pharmacological management of unipolar depression

  2013cites this paper
• A pooled analysis of six month comparative efficacy and tolerability in four randomized clinical trials: agomelatine versus escitalopram, fluoxetine, and sertraline

  2013influential citation
• Does adding noradrenaline reuptake inhibition to selective serotonin reuptake inhibition improve efficacy in patients with depression? A systematic review of meta-analyses and large randomised pragmatic trials

  2013cites this paper
• Upregulation of the dorsal raphe nucleus-prefrontal cortex serotonin system by chronic treatment with escitalopram in hyposerotonergic Wistar-Kyoto rats.

  2013cites this paper
• Blockade of the high‐affinity noradrenaline transporter (NET) by the selective 5‐HT reuptake inhibitor escitalopram: an in vivo microdialysis study in mice

  2013cites this paper
• A systematic review of the efficacy and tolerability of selective serotonin reuptake inhibitors in the treatment of Chinese patients with depressive disorders

  2012cites this paper
• Severe and anxious depression: combining definitions of clinical sub-types to identify patients differentially responsive to selective serotonin reuptake inhibitors.

  2012cites this paper
• Escitalopram for the management of major depressive disorder: a review of its efficacy, safety, and patient acceptability

  2012cites this paper
• On predicting the response to antidepressant treatment

  2012cites this paper
• Surrogate markers of treatment outcome in major depressive disorder.

  2012cites this paper
• Pharmacological treatment of unipolar depression.

  2012cites this paper
• Female sexual dysfunction in patients treated with antidepressant-comparison between escitalopram and fluoxetine.

  2012cites this paper
• Treatment of Comorbid Anxiety and Depression with Escitalopram: Results of a Post-Marketing Surveillance Study

  2012cites this paper
• Cognitive-Behavioural Therapy Combined with Antidepressants for Major Depressive Disorder

  2012influential citation
• Agomelatine: a narrative review.

  2011cites this paper
• Remission with venlafaxine extended release or selective serotonin reuptake inhibitors in depressed patients: a randomized, open-label study.

  2011cites this paper
• Second-generation antidepressants.

  2011cites this paper
• Cibles sérotoninergiques et non sérotoninergiques des ISRS : approches pharmacologique et génétique in vivo chez la souris

  2011cites this paper
• Venlafaxine or a second SSRI: Switching after treatment failure with an SSRI among depressed inpatients: a retrospective analysis.

  2011cites this paper
• Assessing the ‘true’ effect of active antidepressant therapy v. placebo in major depressive disorder: use of a mixture model

  2011cites this paper
• Safety Considerations in Drug Treatment of Depression in HIV-Positive Patients

  2011cites this paper
• Strategies to achieve clinical effectiveness: refining existing therapies and pursuing emerging targets.

  2011cites this paper
• Examination of the Utility of Psychotherapy for Patients with Treatment Resistant Depression: A Systematic Review

  2011cites this paper
• Efficacy and safety of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, randomized, double-blind, flexible-dose study

  2011cites this paper
• Testing anxious depression as a predictor and moderator of symptom improvement in major depressive disorder during treatment with escitalopram

  2011cites this paper
• Efficacy of escitalopram compared to citalopram: a meta-analysis.

  2011cites this paper
• Clinical trial evidence for treatment of depression in heart failure.

  2011cites this paper
• Escitalopram, an antidepressant with an allosteric effect at the serotonin transporter—a review of current understanding of its mechanism of action

  2011cites this paper
• Comparative efficacy of escitalopram in the treatment of major depressive disorder

  2011influential citation
• The Noradrenergic Action in Antidepressant Treatments: Pharmacological and Clinical Aspects

  2011cites this paper
• Escitalopram versus serotonin noradrenaline reuptake inhibitors as second step treatment for patients with major depressive disorder: a pooled analysis

  2010influential citation